The Seattle Seahawks have no reason to move on from Sam Darnold anytime soon. He's proven he's a solid starter and good enough to get a team to the Super Bowl. His NFC Championship performance against ...

Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...

The SEAP II project targets high-quality light oil reserves in the Sergipe-Alagoas Basin, specifically in the Budião, Budião Northwest, and Budião Southeast fields. These deposits are located ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Sagimet Biosciences (SGMT). The reason why I want to go over this biotech next is because just ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key clinical candidates for these companies: ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is part of a new ...

The Metro Tunnel Project features Alstom’s CBTC technology in combination with traditional signalling systems and includes five newly opened stations. Credit: Alstom SA. Alstom has delivered its ...

Giants fans have one more thing to be thankful for today. San Francisco reached an agreement with veteran left-handed reliever Sam Hentges on a one-year, $1.4 million contract, FanSided’s Robert ...

The European Space Agency has completed the Orion service module for NASA's Artemis 4 mission to the moon, which was saved from cancellation earlier this year by the U.S. Congress When you purchase ...

Rarely has a month gone by in 2025 without OpenAI signing another multibillion-dollar data center deal. In a lengthy post on X on Thursday, OpenAI CEO Sam Altman publicly clarified the totals. “We ...

OpenAI is on track to generate more than $20 billion in annualized revenue this year, Sam Altman said. The company said it has plans to grow to hundreds of billions in revenue by 2030. OpenAI has ...

UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development. New Jersey-based UroGen forked ...